Shares of vaccine makers, including Moderna (MRNA), BioNTech (BNTX), Pfizer (PFE), Novavax (NVAX), Vaxcyte (PCVX) and GSK (GSK) moved lower at the end of the trading day following reports that ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...

TORONTO — Health Canada has approved Moderna's mRNA vaccine to protect against respiratory ... manufactured by GSK, and Abrysvo, made by Pfizer. Earlier this year, the National Advisory ...

It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild ...

GlaxoSmithKline places its shingles vaccine ... "Our goal is to develop an mRNA vaccine with a favourable safety profile and high efficacy, which is at the same time more easily scalable to ...